Table 3.
Population-Based Association Between CCHD and PHEO-PGL
| PHEO-PGL |
P Value | Univariate |
Multivariable |
||||
|---|---|---|---|---|---|---|---|
| Yes | No | OR | 95% CI | OR | 95% CI | ||
| Age, y | 55.9 ± 0.1 | 53.2 ± 0.1 | <.0001 | 1.013 | 1.012–1.015 | 1.013 | 1.012–1.014 |
| Female, % | 61.2 ± 0.3 | 51.8 ± 0.1 | <.0001 | 1.5 | 1.4–1.5 | 1.5 | 1.4–1.5 |
| Cyanotic CHD, per 105 | 4.7 ± 2.0 | 0.9 ± 0.0 | <.0001 | 5.5 | 2.4–12.5 | 6.0 | 2.6–13.7 |
| Noncyanotic CHD, per 105 | 19.6 ± 3.0 | 21.9 ± 0.7 | 0.48 | 0.9 | 0.7–1.2 | 0.9 | 0.7–1.5 |
| MEN, per 105 | 15.9 ± 3.1 | 0.3 ± 0.0 | <.0001 | 60.9 | 41.0–90.6 | 59.8 | 40.0–89.6 |
| VHL, per 105 | 26.8 ± 4.7 | 1.4 ± 3.1 | <.0001 | 19.7 | 14.3–27.3 | 15.9 | 11.5–22.1 |
| NF, per 105 | 34.8 ± 5.8 | 3.4 ± 0.1 | <.0001 | 10.3 | 7.4–14.2 | 10.8 | 7.8–15.0 |
| Renal cell cancer, per 105 | 207.3 ± 10.9 | 24.6 ± 0.5 | <.0001 | 8.6 | 7.8–9.4 | 8.2 | 7.5–9.1 |
| Hypertension, % | 62.6 ± 0.4 | 42.2 ± 0.0 | <.0001 | 2.3 | 2.2–2.4 | 2.2 | 2.2–2.3 |
| Hypothyroidism, % | 8.3 ± 0.2 | 6.8 ± 0.0 | <.0001 | 1.24 | 1.18–1.31 | 1.04 | 0.98–1.09 |
| Diabetes, % | 26.1 ± 0.4 | 22.7 ± 0.1 | <.0001 | 1.21 | 1.17–1.25 | 1.12 | 1.09–1.16 |
Results are shown as univariate and multivariable adjusted ORs. Data for nonpregnant patients 18–75 years old hospitalized between 2000 and 2009 were analyzed to determine the population-based frequency of hospitalization for cyanotic CHD and PHEO-PGL. PHEO-PGL was defined as PHEO (ICD-9 codes 194.0, 227.0, 255.6), PGL (codes 194.5/6, 237.3), or carotid body tumor (codes 194.5, 227.5). Cyanotic CHD was defined as any diagnostic code for CHD plus one of the following: cyanosis, hypoxemia, or secondary erythrocytosis (ICD-9 782.5, 289.0, 799.0). Multivariable logistic regression was performed, adjusting for age, gender, and established PHEO-PGL genetic syndromes and phenotypes associated with such syndromes, such as MEN (ICD-9 code 258.0), VHL (ICD-9 code 759.6), and NF (ICD-9 code 237.7), and hypertension diagnosis and renal cell cancer.